A Phase 2 Multicenter Study of CNTO 328 (Anti IL [interleukin]-6 Monoclonal Antibody) in Subjects with Relapsed or Refractory Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 12 Jul 2013
At a glance
- Drugs Siltuximab (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 03 Mar 2010 Status changed from active, no longer recruiting to completed.
- 21 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.